PMI

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-1.7M ExitQ4 2025 $1.7M -- --

News

gurufocus.comPhilip Morris International Announces New Regional Leadershipgurufocus.comJun 18

businesswire.comPhilip Morris International Announces New Regional Leadershipbusinesswire.comJun 18

globenewswire.comPicard Medical and SynCardia to Present New In Vivo Emperor Total Artificial Heart Data and Patient Outcome Research at ASAIO 2026globenewswire.comJun 16

prnewswire.comKuehn Law Encourages Investors of Picard Medical Inc. to Contact Law Firmprnewswire.comJun 9

globenewswire.comKuehn Law Encourages Investors of Picard Medical Inc. to Contact Law Firmglobenewswire.comJun 4

Trade PMI

About Picard Medical, Inc.

Picard Medical, Inc., through its associated companies, is dedicated to the entire process of medical device commercialization, from initial design and manufacturing to production, distribution, marketing, and sales. A key product in its portfolio is the SynCardia TAH, a sophisticated total artificial heart specifically engineered to supplant a failing human heart in individuals afflicted with advanced cardiac disease. The firm's market presence extends across the United States, Europe, and other international regions. Established in 2021, Picard Medical maintains its primary operations in Tucson, Arizona, functioning as a direct subsidiary of Hunniwell Picard I, Llc.

CEO: Patrick N. J. Schnegelsberg
IPO Date: Aug 22, 2025

Market Data

Open: $0.175
High: $0.1911
Low: $0.1719
Volume: 4.4M
Avg Volume: 28M
52W High: $13.68
52W Low: $0.11

Valuation

Market Cap: $284M
Enterprise Value: $287M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-16M
Revenue: $4.9M
Net Income: $-27M
Cash: $7.5M
Debt: $7.0M

Events

EarningsSep 10

EPS est. -0.03